DURHAM, N.C. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer of Chimerix and Mike Andriole , Chief

– Received U.S. Food and Drug Administration (FDA) Approval for TEMBEXA ® (brincidofovir) for the Treatment of Smallpox – – Blinded Independent Central Review (BICR) of ONC201 Registration Cohort in Recurrent H3 K27M-mutant Glioma Expected in Fourth Quarter 2021 – – Conference Call at 8:30 a.m.

DURHAM, N.C. , Aug. 03, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer, will participate in a panel discussion

DURHAM, N.C. , July 29, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, August 5,

– First smallpox antiviral approved for all age groups, including infants, and patients who have difficulty swallowing – DURHAM, N.C. , June 04, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and

DURHAM, N.C. , May 25, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer of Chimerix , will present a corporate

DURHAM, N.C. , May 19, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced upcoming oral and poster presentations at the American Society of Clinical Oncology

DURHAM, N.C. , May 13, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer, and Mike Andriole, Chief Business and

– BCV PDUFA Date Set for July 7 and ONC201 Blinded Independent Central Review Expected in Second Half of 2021 – – DSTAT COVID 19 Trial Advances to Cohort 3 at Higher Dose – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a

DURHAM, N.C. , April 29, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, May 6, 2021